American CryoStem to Present at OneMedForumNY 2013

EATONTOWN, N.J., June 26, 2013 (GLOBE NEWSWIRE) -- American CryoStem Corporation (OTCQB:CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced that the Company has been invited to present at OneMedForumNY 2013 to be held at the Metropolitan Club in New York City, June 26-27, 2013.

OneMedForumNY 2013 will feature over 40 private and public companies with sector-altering technology and a growing reputation. Technologies at the benchtop level will present alongside revenue-positive market-stage companies. The forum is a gathering of leading investors and management of some of the most promising emerging life science companies in Asia and North America. Through panels, workshops and up-close programming with top industry leaders, attendees will explore strategies for company growth, and finance with healthcare investors looking for outsized returns.

WHO:  John Arnone – Chairman and CEO
  Anthony Dudzinski – COO
WHEN:  Thursday, June 27, 2013
  2:50PM ET
WHERE:  The Metropolitan Club
  Morton Room
  One East 60th Street
  New York, New York

About OneMedForum

Launched in 2010 by OneMedPlace, OneMedForumNY includes an audience of institutional investors, high net worth individual investors, family offices, business development executives throughout the US and Europe building and financing high growth medical technology, healthcare and life science companies. For more information, visit

About American CryoStem Corporation

A pioneer in the fields of Regenerative and Personalized Medicine, American CryoStem is a developer, marketer and global licensor of patented adipose tissue based cellular technologies and related proprietary services with a focus on clinical processing, commercial bio-banking and application development for adipose (fat) tissue and autologous adipose-derived regenerative cells (ADRCs). The Company maintains a strategic portfolio of intellectual property and patent applications that form its Adipose Tissue Processing Platform, which supports and promotes a growing pipeline of biologic products and processes, clinical services and international licensing opportunities. Through its ACS Laboratories division, the Company operates an FDA registered, cGMP compliant human tissue processing, cryo-storage and cell culture and differentiation media development facility in Mount Laurel, New Jersey. For more information, please visit and


Contact Data